IPO Timeline
Broker Results (T-2)
2023-05-04
Some brokers release in afternoon
Grey Market (T-1)
2023-05-05
Afternoon
HKEX Allotment (T-1)
2023-05-05
Evening
Registrar Allotment (T-1)
2023-05-05
Evening
Listing Day (T)
2023-05-08
First day of trading
Company Overview
| Stock Name | 绿竹生物－Ｂ |
|---|---|
| Stock Code | 02480 |
| Company Full Name | 绿竹生物－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家致力于開發創新型人類疫苗和治療性生物制劑，以預防和控制傳染性疾病，并治療癌癥和自身免疫性疾病的生物技術公司。 |
| Listing Date | 2023-05-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市通州區工業開發區廣通街3號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.luzhubiotech.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 32.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 46.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 34,072,640 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 6,560 |
| 2 lots | 400 | HK$ 13,120 |
| 3 lots | 600 | HK$ 19,680 |
| 4 lots | 800 | HK$ 26,240 |
| 5 lots | 1,000 | HK$ 32,800 |
| 6 lots | 1,200 | HK$ 39,360 |
| 7 lots | 1,400 | HK$ 45,920 |
| 8 lots | 1,600 | HK$ 52,480 |
| 9 lots | 1,800 | HK$ 59,040 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 22.0 |
|---|---|
| First Day Open | HK$ 31.5 |
| First Day Change | -32.93% |
| First Day Volume | 2796200.0 |
| First Day Turnover | 76911300.0 |
Use of Proceeds
| Use of Proceeds | 1、約58.2%（或140.7百萬港元）將主要用于核心產品LZ901的臨床開發、制造及商業化； 2、約22.1%（或53.4百萬港元）將主要用于K3的臨床開發及制造； 3、約16.1%（或38.8百萬港元）將主要用于建設于珠海的商業生產設施，其是大型、定制及不可拆卸的生產設施； 4、約3.6%（或8.7百萬港元）將主要用作營運資金及其他一般公司用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (3)
中国国际金融香港证券有限公司 CE AEN894
国泰君安证券（香港）有限公司 CE ABY236
建银国际金融有限公司 CE AJO225
Joint Bookrunners (14)
中国国际金融香港证券有限公司 CE AEN894
国泰君安证券（香港）有限公司 CE ABY236
建银国际金融有限公司 CE AJO225
Guosen Securities (HK) Capital Company Limited CE AUX600
复星国际证券有限公司 CE AAF432
百惠证券有限公司 CE BPQ161
中银国际亚洲有限公司 CE AET863
艾德证券期货有限公司 CE BHT550
农银国际证券有限公司 CE ACX411
华盛资本证券有限公司 CE AUL711
富途证券国际（香港）有限公司 CE AZT137
信银（香港）资本有限公司 CE AEQ982
中州国际融资有限公司 CE ABC734
Dragonstone Capital Management Limited CE BGM303
Joint Lead Managers (16)
中国国际金融香港证券有限公司 CE AEN894
国泰君安证券（香港）有限公司 CE ABY236
建银国际金融有限公司 CE AJO225
Guosen Securities (HK) Capital Company Limited CE AUX600
复星国际证券有限公司 CE AAF432
百惠证券有限公司 CE BPQ161
中银国际亚洲有限公司 CE AET863
艾德证券期货有限公司 CE BHT550
农银国际证券有限公司 CE ACX411
华盛资本证券有限公司 CE AUL711
富途证券国际（香港）有限公司 CE AZT137
信银（香港）资本有限公司 CE AEQ982
中州国际融资有限公司 CE ABC734
Dragonstone Capital Management Limited CE BGM303
GF Securities (Hong Kong) Brokerage Limited CE AOB364
光银国际资本有限公司 CE BGH296
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 156,993,920 HKD | — | 46.09% | — | 6 months | 2023-11-08 |
Directors & Management
| Chairman | 孔健 |
|---|---|
| Company Secretary | 劉斯宇,賴浩恩 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 孔健(28.79%);張琰平(9.98%);北京亦莊生物醫藥并購投資中心(有限合伙)(9.70%);北京亦莊二期生物醫藥產業投資基金(有限合伙)(9.05%);北京賽升藥業股份有限公司(6.79%);珠海橫琴綠竹企業管理合伙企業(有限合伙)(6.08%);建銀國際資本管理(天津)有限公司(5.76%) |
|---|
Subscription Tiers
IPO Timeline
